Cipla Jumps 5%, Snaps 4-Session Losing Streak After FY27 Margin & US Growth Guidance

As on 14 May 2026,

remained in focus after management guided for an 18.5%–20% EBITDA margin for FY27 and projected crossing a $1 billion US run-rate by the end of FY27. Managing Director and Global CEO Achin Gupta highlighted confidence in the company’s pipeline-led recovery during a recent media interaction. The positive commentary triggered strong buying interest in the counter, with Cipla shares rallying nearly 5% intraday yesterday. The move also helped the stock snap its four-session losing streak, indicating renewed momentum after recent weakness. The development kept pharma stocks in focus amid improving sentiment around export-driven businesses and margin visibility in the sector. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.